All content for AUAUniversity is the property of American Urological Association and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction
Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS
The Latest Breakthroughs in mHSPC
CME Available: https://auau.auanet.org/node/43825
After participating in this CME activity, participants will be able to:
1.Evaluate the concept of personalized therapy and its importance in the treatment of de novo mHSPC.
2.Implement current clinical guidelines for biomarker testing in mHSPC.
3.Explain the role of the PI3K/AKT pathway in prostate cancer biology.
4.Explore collaborations between urologists, oncologists, radiologists, and other healthcare professionals in managing de novo mHSPC.
5.Employ strategies to manage and mitigate common adverse events associated with AKT inhibitors and other therapies used in mHSPC.
Acknowledgements:
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
AUAUniversity
AUA2025: Key Takeaways: Lower Urinary Tract Reconstruction
Presenters: George E. Koch, MD & Kurt A. McCammon, MD, FACS
